<DOC>
	<DOC>NCT01957904</DOC>
	<brief_summary>The study is designed to confirm the acute safety and performance of the ArterXÂ® Surgical Sealant as a hemostatic agent. The study will collect data in support of publications and future product labeling revisions, to provide additional clinical information on use and further details regarding product safety.</brief_summary>
	<brief_title>ArterX Safety and Efficacy Study for Cardiac Indications</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>&gt;18 years of age, Male or female If female, subject is postmenopausal, has no child bearing potential or has a negative serum or urine pregnancy test within 7 days of the index procedure and is practicing abstinence or a highly effective method of contraception for the duration of the study. The subject or guardian must provide written Informed Consent using a form that is reviewed and approved by the Ethics Committee. The subject is willing and able to be contacted for 3 months followup and attend followup visits as needed per protocol. The subject is determined by the surgeon to be at risk for poor hemostasis. Subject undergoing emergency surgery. Subject undergoing minimally invasive surgery. Subject has clinically significant medical, psychiatric, or cognitive illness or drug/alcohol abuse that in the opinion of the investigator would affect the subject's safety or compliance with study assessments or followup. Subject has immune system disorders/immunodeficiency or immunosuppression. Subject has participated in another clinical study within 30 days prior to surgery or has received an investigational drug or device within the past 30 days. Subject is pregnant, may become pregnant or is currently breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ArterX, surgical sealant</keyword>
</DOC>